Vir Biotechnology, Inc. Common Stock (VIR) News
Latest headlines that mention VIR, newest first · each headline opens the original publisher
- Last price
- $11.12
- Day change
- -3.47%
- Next earnings
- 2026-11-04
VIR headlines
latest coverageHDV combination therapy achieved 88% viral clearance, advancing toward Phase 3 readouts.
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings.
Image source: The Motley Fool. May 6, 2026 Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
Also mentioned with VIR
30dHeadlines that tag both tickers
VIR news alerts
Get an alert by email or push when a new headline mentions VIR.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.